Own CSL shares? Here's what brokers are saying about its R&D pipeline

What are analysts saying about CSL's R&D pipeline?

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares are pushing higher on Monday.

At the time of writing, the biotherapeutics giant's shares are up 0.5% to $276.85.

Why are CSL shares rising?

CSL shares are rising on Monday after brokers responded positively to the company's research and development (R&D) update.

One of those brokers was Morgans, which has responded by retaining its add rating and $312.20 price target on the company's shares.

Morgans was pleased with the update and notes that a decent proportion of the pipeline has the potential to become standard of care treatments. It commented:

Internal efforts and the Vifor acquisition have seen the R&D pipeline grow c70% with the majority late-stage programs. Management is optimistic of the future "conservatively" estimating at least 10 compounds (c20% of the total pipeline) having the potential to be standard of care for the targeted patient group.

Key catalysts include: potential approval and launch of the first-ever hemophilia B gene therapy EtranaDez; Phase 3 data for anti-FXIIa antibody garadacimab in HAE; and Phase 2 recruitment completion of CSL112 for reducing secondary heart attacks.

What else are brokers saying?

The team at Citi was equally positive and has retained its buy rating and $340.00 price target. Like Morgans, the broker has highlighted the CSL112 therapy as a key highlight. It stated:

CSL held its annual event updating the market on its R&D programs. The R&D budget is significant at US$1.16bn in FY22 or ~11% of revenue. CSL will continue to spend ~10-11% of revenue on R&D annually. The pipeline now includes assets from recently acquired Vifor with two assets in Phase 3. Our $340 TP includes $22.40 for the R&D portfolio (down from $23 on delays) – the main asset remains CSL112 (cardiovascular) at $20/share on which we will get Phase 3 data in Q1 CY24. Maintain Buy, $340 TP.

Finally, Goldman Sachs responded by maintaining its neutral rating and $291.00 price target. Its analysts note that the garadacimab (CSL312) product has the potential to be a "pipeline in a product" thanks to multiple end use possibilities. The broker explained:

CSL312 is a humanised anti-factor XIIa monoclonal antibody in development for multiple indications including as a subcutaneous therapy for HAE, with the potential for administration every 4 weeks (vs. every 2-3 days for Haegarda). Given its early position in the coagulation cascade, there is also potential application in various other disorders (including fibrosis, cardiovascular and inflammatory indications).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »